Dr Lee received his PhD, in 2002, from The University of Melbourne and the Howard Florey Institute, in the area of neuroscience and pharmacology,
He then worked as a Parkinson's Society Canada Research Fellow at the Toronto Western Hospital in Canada, to investigate the role of abnormal synaptic plasticity in Parkinson's disease. In 2006 he returned to the Florey Neurosciences Institute to investigate the compensatory mechanisms in the brain in Parkinson's disease and drug addiction.
In 2008 he joined PHI.
Dr Lee's research has focuses on gender differences in brain function in normal and diseased states. In particular the research laboratory is focusing on the potential role of the male sex-determining gene SRY in the gender differences in neurological diseases, such as Parkinson's disease.
He has a strong interest in understanding the role of the male-specific gene SRY and the brain and how abnormal regulation of SRY may increase the susceptibility of men to certain neurological disorders, such as Parkinson's disease and schizophrenia.
Animal models of Parkinson's disease and Movement Disorders; Behavioural Pharmacology; Stereotaxic surgery; Neurochemistry, in vivo and in vitro measurements of neurotransmitter release, immunohistochemistry, in situ hybridisation, ligand-receptor binding.
2009 - Project Grants from Rebecca L. Cooper Medical Research Foundation, Helen McPherson Smith Trust, Contributing to Australian Scholarship and Science (CASS) Foundation
2008 - Project Grant from Bethlehem Griffiths Research Foundation
2008 - Travel Grant from CASS Foundation
2007 - Travel Grant from International Brain Research Organisation (IBRO)
Lee, J., Zhu, W.M., Stanic, D., Finkelstein, D.I., Horne, M.H., Henderson, J., Lawrence, A.J., O'Connor, L., Tomas, D., Drago, J., and Horne, M.K. (2008) Sprouting of Dopamine Terminals and Altered Dopamine Release and Uptake in Parkinsonian Dyskinesia. Brain. 131 (pt6), 1574-87.
Horne M.K., Lee, J., Chen, F., Lanning, K., Tomas, D., Lawrence, A.J. (2008) Long term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic and serotonin pathways. J. Neurochem. 106(4), 1731-44.
Lee, J., Gomez-Ramirez, J., Johnston, T., Visanji, N., Brotchie, J.M. (2008) Receptor-activity modifying protein 1 (RAMP1) expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. Synapse. 62(4), 310-313.
Lee, J., Di Marzo, V., and Brotchie, J.M. (2006) Role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology. 51, 557-565.
Brotchie, J.M., Lee, J., and Venderova, K. (2005) L-DOPA-induced dyskinesia in Parkinson's disease. Journal of Neural Transmission,112(3), 359-91.
Johnston, T., Lee, J., Gomez-Ramirez, J., Fox, S.H., and Brotchie, J.M. (2005). A simple rodent in vivo assay for identifying novel drug therapies for L-DOPA-induced dyskinesia. Experimental Neurology. 191(2), 243-250.